Exforge (Amlodipine/Valsartan) for Hypertension
Indications
Exforge is indicated for treating hypertension to lower blood pressure in patients not adequately controlled on monotherapy or as initial therapy in patients likely to need multiple drugs to achieve blood pressure goals 1. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions 1.
The 2024 ESC guidelines strongly support this approach, recommending combination BP-lowering treatment for most patients with confirmed hypertension (BP ≥140/90 mmHg) as initial therapy, with preferred combinations being a RAS blocker (ARB) with a dihydropyridine calcium channel blocker 2. Fixed-dose single-pill combinations like Exforge are specifically recommended to improve adherence 2.
Dosing
Start with Exforge 5/160 mg once daily in patients who are not volume-depleted, with dose titration after 1-2 weeks to a maximum of 10/320 mg once daily as needed 1.
Dosing Algorithm:
- Initial therapy patients: Start 5/160 mg once daily (if not volume-depleted)
- Add-on therapy: Switch patients inadequately controlled on amlodipine or valsartan monotherapy to equivalent or higher combination doses
- Dose titration: Increase after 1-2 weeks if needed; majority of antihypertensive effect occurs within 2 weeks
- Maximum dose: 10/320 mg once daily
- Timing: Take at the most convenient time of day to establish habitual pattern and improve adherence 2
Available Strengths:
- 5/160 mg
- 10/160 mg
- 5/320 mg
- 10/320 mg 1
If blood pressure remains uncontrolled after 3-4 weeks on Exforge, add a thiazide/thiazide-like diuretic as three-drug combination therapy 2, 1.
Contraindications
Absolute contraindications 1:
- Known hypersensitivity to any component
- Pregnancy (causes fetal toxicity, renal dysfunction, and death)
- Coadministration with aliskiren in diabetic patients
Additional contraindications from guidelines 3:
- Neurogenic orthostatic hypotension
- Fibromuscular dysplasia
- Stented renal artery
- Renal artery aneurysm
- Significant renal artery stenosis
Adverse Effects
Common Adverse Effects:
Peripheral edema is the most common side effect (1.4-8.7% depending on dose), with higher rates at intensive dosing 1, 4, 5. The valsartan component helps attenuate amlodipine-induced peripheral edema compared to amlodipine monotherapy 6.
Serious Warnings:
Hypotension (0.4% in uncomplicated hypertension): Volume-depleted patients or those on high-dose diuretics are at highest risk. Correct volume depletion before starting Exforge 1. If excessive hypotension occurs, place patient supine and give IV normal saline if necessary 1.
Risk of myocardial infarction or increased angina: Worsening angina and acute MI can develop after starting or increasing amlodipine dose, particularly in patients with severe obstructive coronary artery disease 1.
Fetal toxicity: Discontinue immediately when pregnancy is detected. Use of drugs acting on the renin-angiotensin system during second and third trimesters causes fetal renal dysfunction, oligohydramnios, skull hypoplasia, anuria, hypotension, renal failure, and death 1.
Overall Tolerability:
In observational studies, adverse reactions occurred in only 3.1% of patients, requiring discontinuation in 0.5% 4. Both treatment regimens are generally well tolerated with placebo-like tolerability profile from the valsartan component 6.
Clinical Efficacy
Exforge provides superior blood pressure reduction compared to monotherapy, with intensive dosing (10/320 mg) achieving greater reductions than moderate dosing (5/160 mg) 7, 5. In the AESCULAP program, BP decreased from 169.3/99.9 mmHg to 129.1/80.3 mmHg at 12 weeks, with 79.5% of patients achieving BP goals 4.
Blood Pressure Goal Achievement:
A patient with baseline BP of 160/100 mmHg has approximately 80% likelihood of achieving <140 mmHg systolic and 85% likelihood of achieving <90 mmHg diastolic on Exforge, compared to 67%/80% on amlodipine alone or 47%/62% on valsartan alone 1.
Target treated systolic BP of 120-129 mmHg in most adults to reduce cardiovascular risk, provided treatment is well tolerated 2.